Investors / United Kingdom / o2h Ventures
o2h Ventures
Venture capital · Cambridge, United Kingdom · Europe
o2h Ventures is a UK fund manager running SEIS/EIS funds, including the o2h Seven Sisters Human Health EIS Growth Fund, which invests in UK biotech companies. It operates from The Mill SciTech Park in Hauxton, Cambridge, where it also incubates small life science companies.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticsdrug discoverylife sciencesincubationeis
Your fit with o2h Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitso2h Ventures lists 35 checked portfolio companies on its own site. Its largest themes are Healthcare & Biotech (94%), Enterprise Software (3%) and AI & Machine Learning (3%). 80% of its companies are based in United Kingdom. It invests most often alongside Angel CoFund, EMV Capital and Future Planet Capital.
No funding round on record names o2h Ventures yet, so the figures come from its portfolio page.
Round figures show recent activity, not o2h Ventures' whole history. Rounds on record name 0 companies; its own site lists 35. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 74th | 36 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 96th | 94% in its largest sector |
| Reach | 70th | 4 countries |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers3394%
- No longer answers00%
- Points to another company26%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 94% | 15% |
| Enterprise Software | 3% | 8% |
| AI & Machine Learning | 3% | 18% |
Co-investor network
who it backs companies with, and who they back togetherCompare o2h Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Portfolio
35 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Acacia Pharma is a commercial stage biopharmaceutical group focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy. | Healthcare & Biotech | Portfolio page | ||
| The company does organism level drug discovery | Healthcare & Biotech | Portfolio page | ||
| Alevin Therapeutics develops transformative safe and effective medicines for patients with life-threatening fibrotic diseases through targeted integrin therapies | Healthcare & Biotech | Portfolio page | ||
| Arecor is a clinical-stage biotech company developing superior therapeutics for people living with diabetes, obesity and other cardiometabolic diseases. | Healthcare & Biotech | Portfolio page | ||
| Atelerix preserves and transports fresh cells, tissues, and blood without cryopreservation using its hypothermic gel technology | Healthcare & Biotech | Portfolio page | ||
| BiVictriX develops therapeutics to target cancer cells, making them vulnerable to precision attack. | Healthcare & Biotech | Portfolio page | ||
| CamGene develops RNA-based medicines for hearing loss | Healthcare & Biotech | Portfolio page | ||
| CardiaTec Biosciences Ltd is a company that decodes cardiovascular disease biology | Healthcare & Biotech | Portfolio page | ||
| ClotProtect Therapeutics is developing a small molecule anti-fibrinolytic to transform how acute bleeding is treated. | Healthcare & Biotech | Portfolio page | ||
| Cortirio brings imaging to the point of care to help with stroke diagnosis and treatment | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Five Alarm Bio is targeting an unexplored mechanism of aging to delay or prevent the onset of a range of age-related diseases, with broad potential therapeutic application. | Healthcare & Biotech | Portfolio page | ||
| Helus Pharma develops novel serotonergic agonists for the treatment of mental health conditions | Healthcare & Biotech | Portfolio page | ||
| Kuano combines quantum physics-based molecular design with an agent-enabled scientific platform for drug discovery and molecular innovation. | Healthcare & Biotech | Portfolio page | ||
| Metrion Biosciences provides preclinical drug discovery services, including ion channel screening, cardiac safety screening, and neuroscience services. | Healthcare & Biotech | Portfolio page | ||
| NeoPhore develops a therapeutic approach that blocks DNA Mismatch Repair to make tumors sensitive to immunotherapy. | Healthcare & Biotech | Portfolio page | ||
| Neurocentrx is developing a new drug- and software combination investigational product designed to offer a trusted prescription for psychiatrists and their patients to safely access the rapid-acting antidepressant effects of ketamine-based care. | Healthcare & Biotech | Portfolio page | ||
| Oppilotech simulate biology using a predictive computational modelling platform to provide insights into treating diseases. | Healthcare & Biotech | Portfolio page | ||
| Oxford Drug Design designs and develops innovative therapeutics from pioneering Oxford science | Healthcare & Biotech | Portfolio page | ||
| Pencil Biosciences is developing a synthetic platform for gene editing. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- o2hventures.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Companies checked
- 35
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get o2h Ventures' profile as data
Pull o2h Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/o2hventures.com
# also
GET /v1/firms/o2hventures.com/portfolio
GET /v1/firms/o2hventures.com/coinvestors
GET /v1/firms/o2hventures.com/news